Manhattan Research Releases New Research on DTC's Impact on Pharma Website Visitation

Manhattan ResearchNuvaRing® and Latisse® are the top pharmaceutical brands in terms of having the highest percentage of overall product website traffic driven by their DTC television advertisements, according to pharmaceutical and healthcare market research company Manhattan Research. The findings are from ePharma Consumer® v9.0, the company's newly released study focused on the attitudes and behaviors of consumers researching prescription drug information online. NuvaRing®, a contraceptive manufactured by Merck, jumped five spots from last year to take the top ranking.

Latisse®, an eyelash enhancement treatment launched last year by Allergan, was also successful in driving individuals online for additional information.

Top Pharma Product Sites in Terms of Percentage of Traffic Driven by DTC Television Ads

1. NuvaRing®
2. Latisse®
3. Cialis®
4. Boniva®
5. Abilify®
6. Gardasil®
7. Yaz®
8. Viagra®
9. Levitra®
10. Lunesta™

Among consumers online for pharma information and sites for which n>60

"In today's multi-channel world, marketing initiatives must be designed to work together for optimal results," says Meredith Ressi, Vice President of Research at Manhattan Research. "While the television ad is critical to building awareness, for many patients, the Internet is a next stop for learning more before going on to speak to their physician about a product."

Mrs. Ressi will discuss these findings and more during a complimentary webinar to be held on Thursday, January 21st at 11:00 AM, EST.

Complimentary Pharma eMarketing Webinar - Thursday, January 21, 2010

Manhattan Research Vice President of Research Meredith Ressi will preview the latest trends in how consumers research and interact with online prescription drug information from the ePharma Consumer® study. Key topics include:

  • Which brands (250+ tracked) are the most successful in driving consumers online and satisfying them with engaging content? How does your brand measure up to the competition?
  • What roles do search, social media, and online video play in the ePharma landscape?
  • What are some of the general attitudes and future interests of consumers seeking prescription drug information online?
ePharma Consumer® v9.0: Online Pharmaceutical Information-Seeking Landscape

Thursday, January 21, 11:00 AM EST

Register here: https://www2.gotomeeting.com/register/491612787

About ePharma Consumer® v9.0
ePharma Consumer® v9.0 is focused on the attitudes and behaviors of consumers seeking pharmaceutical information online. The study was conducted via online survey in Q4 2009 among 6,575 adults (age 18+). ePharma Consumer® also provides data on more than 250 pharmaceutical product websites. Clients can segment the broad market research to provide in-depth data on more than 85 condition groups. For additional product and subscription information, please visit http://www.manhattanresearch.com/epc.

About Manhattan Research
Manhattan Research, a Decision Resources, Inc. company, is a leading market research and advisory services firm for global pharmaceutical and healthcare companies. For more information, visit http://www.manhattanresearch.com.

About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.decisionresourcesinc.com.

Most Popular Now

New strategy to treat Parkinson's disease

Northwestern Medicine scientists have used patient-derived neurons to develop and test a new strategy to treat Parkinson's disease by mitigating the effects of harmful ge...

AI could offer warnings about serious side effects…

The more medications a patient takes, the greater the likelihood that interactions between those drugs could trigger negative side effects, including long-term organ dama...

OPKO and Pfizer announce positive Phase 3 top-line…

OPKO Health Inc. (NASDAQ: OPK) and Pfizer Inc. (NYSE: PFE) announced that the global Phase 3 trial evaluating somatrogon dosed once-weekly in pre-pubertal children with g...

Trastuzumab deruxtecan granted FDA Priority Review…

AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) today announced that the US Food and Drug Administration (FDA) has accepted for review the Biologics Lice...

The Bristol-Myers Squibb-Pfizer Alliance and Fitbi…

The Bristol-Myers Squibb-Pfizer Alliance and Fitbit announced at the TIME 100 Health Summit in New York that they are working together to help drive timely diagnosis of a...

Nplate® (romiplostim) now approved for earlier use…

Amgen (NASDAQ:AMGN) announced that the U.S. Food and Drug Administration (FDA) approved Amgen's Supplemental Biologics License Application (sBLA) for Nplate® (romiplostim...

Novartis announces that Jakavi® (ruxolitinib) meet…

Novartis today announced positive topline results from the Phase III REACH2 study evaluating Jakavi® (ruxolitinib) in patients with steroid-refractory acute graft-versus-...

Bayer launches LifeHub UK focused on artificial in…

Bayer launched LifeHub UK to accelerate and optimize disease detection and data-driven drug discovery by developing artificial-intelligence-enabled imaging solutions. The...

Amgen recommends rejection of 'mini-tender' offer …

Amgen (NASDAQ:AMGN) today announced that it has been notified of an unsolicited "mini-tender" offer dated Oct. 11, 2019, made by TRC Capital Corporation, a private Canadi...

Antibody-based eye drops show promise for treating…

Researchers at the University of Illinois at Chicago are the first to identify the presence of a specific type of antibody, called anti-citrullinated protein autoantibodi...

First entirely digital clinical trial encourages p…

As little as a daily ping on your phone can boost physical activity, researchers from the Stanford University School of Medicine and their collaborators report in a new s...

Abbott and Omada Health partner to offer integrate…

Abbott (NYSE: ABT) and Omada Health announced today they are partnering to integrate Abbott's revolutionary FreeStyle Libre system, a continuous glucose monitoring (CGM) ...